Literature DB >> 15848991

Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells.

Hideo Hashizume1, Masahiro Takigawa.   

Abstract

We report a case of tribenoside-induced hypersensitivity syndrome associated with cytomegalovirus reactivation and investigation of the immunological characteristics of the circulating and skin-infiltrating lymphocytes. Activated CD8+ T cells outnumbered CD4+ cells in both the circulation and the skin lesions. Upon in vitro stimulation with the drug, CD4+ cells proliferated and produced interferon-gamma. The circulating CD8+ cells used limited T-cell receptor Vbetas, some of which are restricted to cytomegalovirus-derived peptide in the context of the HLA-A2 haplotype. CD8+ cells and cytomegalovirus-containing cells closely co-localized in the skin lesions. These results suggested that CD4+ cells were drug-reactive, whereas cytomegalovirus activated CD8+ cells in the present case. These two cell types seemed to play a distinct role in drug-induced hypersensitivity syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848991     DOI: 10.1080/00015550410024094

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  3 in total

Review 1.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

2.  Structural Elements Recognized by Abacavir-Induced T Cells.

Authors:  Daniel Yerly; Yuri Andreiw Pompeu; Ryan J Schutte; Klara K Eriksson; Anette Strhyn; Austin W Bracey; Soren Buus; David A Ostrov
Journal:  Int J Mol Sci       Date:  2017-07-07       Impact factor: 5.923

Review 3.  Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).

Authors:  Fumi Miyagawa; Hideo Asada
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.